Introducing “HEDGE”: sequential intravesical gemcitabine-based thermochemotherapy (HIVEC) plus docetaxel as a potential novel bladder-sparing strategy for BCG-unresponsive non-muscle-invasive bladder cancer. Arch Ital Urol Androl [Internet]. 2026 Sep. 9 [cited 2026 Sep. 10]; Available from: https://www.pagepressjournals.org/aiua/article/view/15738